retatrutide phase 2 trial obesity nejm 2023 triple agonist 2023年度回顧】 Notable Articles of Day 3: Triple–Hormone-Receptor for — A Trial. N Engl J Med 2023; 389:514-526. 製圖：Sardinosis Retatrutide: A Triple Agonist Shaping

01Mechanism of action Retatrutide is the first triple incretin-mimetic agonist to reach phase II/III clinical development

Dialog Health's healthcare-specific platform delivers: 96% patient reach rates (compared to 30% for phone calls) 71% response rates in just 13 minutes 66% decrease in same-day cancellations across all procedures Fill out this quick form and one of our healthcare communication experts will reach out to schedule a15-minute video call

Both methods are widely used, but they operate in completely different waysone is a GLP-1 weight loss injection that controls hunger biologically, while the other is a structured eating pattern focused on timing

When GLP-1 is released, it binds to specific GLP-1 receptors

2025;doi:10.1001/jamaneurol.2025.0353

At its core, AltRx falls into the growing category of online prescription weight loss services, designed for people who want a more accessible and flexible alternative to traditional healthcare systems